We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer (LEGS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00604994
Recruitment Status : Completed
First Posted : January 30, 2008
Last Update Posted : August 20, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
This project will conduct a prospective, longitudinal, observational cohort study to assess the onset and incidence of lymphoedema, as well as investigate factors associated with its development among women newly diagnosed with gynaecological cancers in 2008 to 2011.

Condition or disease
Female Genital Diseases Ovarian Cancer Cervical Cancer Endometrial Cancer Vulval Cancer

Detailed Description:

Pathological swelling of the lower limbs (lymphoedema) is widely accepted to be a common consequence of treatment for gynaecological cancer. It is both a serious and debilitating complication, associated with significant morbidity, which impacts physically and emotionally on otherwise healthy women. Lymphoedema can also affect patients' ability to earn an income, especially if their work requires prolonged periods of standing or walking.

The causes of lymphoedema are largely unknown with clinical data scarce regarding its onset time and incidence after gynaecological cancer treatment.

The following hypotheses will be tested to address the aims of the project:

  1. At least 20% of patients will develop lower-limb lymphoedema following gynaecological cancer treatment.
  2. Patient's age, as well as their body mass index (BMI), area of residence, degree of physical exercise, type of disease (uterine, cervical, ovarian, vulval/vaginal cancer; benign disease), mode of treatment (extent of lymph node dissection, radiotherapy, chemoradiation) and delay in wound healing are independent risk factors for lower-limb lymphoedema.
  3. Patients who develop lymphoedema after gynaecological cancer treatment, will experience increased pain, lower quality of life (including worse body-image), and decreased sexual & financial well-being, compared to those who do not develop lymphoedema.
  4. There will be at least 10% difference in the incidence of lower-limb lymphoedema between patients treated for gynaecological cancer compared to benign diseases.

Study Design

Study Type : Observational
Actual Enrollment : 761 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer
Study Start Date : June 2008
Primary Completion Date : January 2013
Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphedema
U.S. FDA Resources

Groups and Cohorts

Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
Patients without malignant gynaecological cancers

Outcome Measures

Primary Outcome Measures :
  1. Time of onset of lymphoedema after gynaecological cancer treatment. [ Time Frame: 2 years ]
  2. Incidence of lymphoedema after gynaecological cancer treatment. [ Time Frame: 2 years ]
  3. Point prevalence of lymphoedema after gynaecological cancer treatment. [ Time Frame: 2 years ]
  4. Severity of lymphoedema after gynaecological cancer treatment. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Prevalence of key risk factors of post-treatment lymphoedema among patients with gynaecological cancer. [ Time Frame: 2 years ]
  2. Impact of risk factors on development of lymphoedema. [ Time Frame: 2 years ]
  3. Lymphoedema development in patients treated for gynaecological cancer compared to patients with benign disease. [ Time Frame: 2 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women with gynaecological conditons requiring treatment

Inclusion Criteria:

  • Patients scheduled for surgery of benign or malignant gynaecological diseases as determined jointly by the surgeon and the patient.
  • Non-pregnant female patients.
  • Over 18 years of age at time of surgery.
  • Patients who understand the conditions of the study and are willing to participate for the length of the prescribed term of follow-up.
  • Patients who are capable of, and have given, informed consent to their participation in the study.

Exclusion Criteria:

  • Patients with a pacemaker.
  • Allergies against adhesive electrodes and extensive internal metal plates are ineligible for BIS measurement.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00604994

Australia, New South Wales
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Australia, Queensland
The Wesley Hospital
Auchenflower, Queensland, Australia, 4066
Greenslopes Private Hospital
Greenslopes, Queensland, Australia, 4120
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia, 4029
Mater Health Services
South Brisbane, Queensland, Australia, 4101
Australia, Victoria
Royal Women's Hospital
Carlton, Victoria, Australia, 3053
Sponsors and Collaborators
Queensland Centre for Gynaecological Cancer
The University of Queensland
Royal Brisbane and Women's Hospital
Mater Health Services, Brisbane
Mater Private Hospital
Queensland Institute of Medical Research
Queensland University of Technology
Australia New Zealand Gynaecological Oncology Group
Cancer Australia
Principal Investigator: Andreas Obermair, MD FRANZCOG CGO Queensland Centre for Gynaecological Cancer
More Information

Additional Information:
Responsible Party: Queensland Centre for Gynaecological Cancer
ClinicalTrials.gov Identifier: NCT00604994     History of Changes
Other Study ID Numbers: LEGS
First Posted: January 30, 2008    Key Record Dates
Last Update Posted: August 20, 2013
Last Verified: August 2013

Keywords provided by Queensland Centre for Gynaecological Cancer:

Additional relevant MeSH terms:
Genital Diseases, Female
Genital Neoplasms, Female
Uterine Cervical Diseases
Uterine Diseases
Lymphatic Diseases
Vulvar Diseases
Uterine Cervical Neoplasms
Endometrial Neoplasms
Vulvar Neoplasms
Uterine Neoplasms
Urogenital Neoplasms
Neoplasms by Site